Sartorius Stedim Biotech SA DIM

Stock XPAR Rating as of Oct 21, 2026

€209.20 −6.20 (2.88%)

As of Oct 22, 2026, 3:35:04 PM Delayed Price Post-Trading: —

Company Report

Sartorius Stedim Earnings: Consumables Underpins Revenue Growth; Shares Are Fairly Valued

Matthew Donen Oct 22, 2026

Sartorius Stedim grew third-quarter sales 7.4% in constant currencies before tariff compensation to customers. Underlying EBITDA margin was 31.1% versus 31.3% a year earlier, which was in line with company-compiled consensus. Management confirmed full-year guidance.

Read Analysis

Price vs Fair Value

View History

DIM is trading at a LOCK|ptN$Fbt premium.

Price

€215.40

Oct 21, 2026

Fair Value

<#y

May 7, 2025

Uncertainty

LOCK|>$

1-Star Price: LOCK|x.^
5-Star Price: LOCK|!.V
Economic Moat: LOCK|>Zz
Capital Allocation: LOCK|>$!PHZ

Bulls Say, Bears Say

Bulls

SSB's CGT product portfolio allows the company to capitalize on long-term growth, should these therapies achieve widespread adoption.

Bears

The high growth in the biopharma market increases the risk of greater competition from better-capitalized peers that have a broader product offering.

Trading Information

Previous Close Price: €215.40
Day Range: €209.20–224.20
52-Week Range: €150.00–225.00
Bid/Ask: €209.00 / €219.00
Shares Outstanding: 97.29M
Market Cap: €20.35B
Volume/Avg: 158,936 / 92,495

Key Statistics

Price/Earnings (Normalized): 53.94
Price/Sales: 6.97
Dividend Yield (Trailing): 0.32%
Dividend Yield (Forward): 0.32%
Dividend Payment Schedule: Apr
Total Yield: 0.32%

Company Profile

Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.

Sector: Healthcare
Industry: Medical Instruments & Supplies
Stock Style Box: Mid Core
Total Number of Employees: 10,477
Website: https://www.sartorius.com

Competitors

Valuation

Metric	DIM	MRK	A
Price/Earnings (Normalized)	53.94	17.63	29.33
Price/Book Value	4.95	2.05	6.81
Price/Sales	6.97	2.93	6.84
Price/Cash Flow	34.44	13.59	26.56

Price/Earnings

DIM

MRK

Financial Strength

Metric	DIM	MRK	A
Quick Ratio	0.48	0.99	1.41
Current Ratio	1.16	1.69	2.05
Interest Coverage	4.24	7.22	16.08

Quick Ratio

DIM

MRK

Profitability

Metric	DIM	MRK	A
Return on Assets (Normalized)	5.40%	4.75%	13.27%
Return on Equity (Normalized)	10.62%	8.32%	24.92%
Return on Invested Capital (Normalized)	7.74%	6.65%	16.95%

Return on Assets

DIM

MRK

Medical Instruments & Supplies Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Intuitive Surgical Inc ISRG	LOCK\|r@^g^!Jz	LOCK\|C%R	$151B
Becton Dickinson & Co BDX	LOCK\|b%	LOCK\|rJMrv	$53B
ResMed Inc RMD	LOCK\|fsLR&h^j	LOCK\|<c@N	$35B
Alcon Inc ALC	LOCK\|l?mHSL	LOCK\|y&#%	$33B
Medline Inc Ordinary Shares - Class A MDLN	LOCK\|W?<RffJ	LOCK\|#qwCt	$31B
West Pharmaceutical Services Inc WST	LOCK\|#!V&Qt#	LOCK\|^?@	$28B
Solventum Corp SOLV	LOCK\|#HXDcT	LOCK\|Y&@	$15B
Baxter International Inc BAX	LOCK\|?Sm	LOCK\|<<Qr	$13B
Repligen Corp RGEN	LOCK\|jR@px>?	LOCK\|!pMS	$11B
The Cooper Companies Inc COO	LOCK\|yh$!b<	LOCK\|g$cS&	$11B